STOCKS TELEGRAPH

Tag: NASDAQ: BNTX

  • Are The Current Prices Weighing On Pfizer And BioNTech, When To Buy These Stock?

    Are The Current Prices Weighing On Pfizer And BioNTech, When To Buy These Stock?

    Without significant reservations, the vaccine from Pfizer and BioNTech was approved for review by the FDA. All the basic parameters of the vaccine have been verified by the Commission that approved the application, including that it is 95 percent successful. Furthermore other significant aspects of the research were revealed. That the vaccine triggers defense at the first injection, however a course of two injections is necessary to get immunity. After the first treatment, it is 52 percent successful (with the minimum FDA requirements of 50 percent).

    Cases of severe side effects, such as paralysis of the facial nerve and swelling of the lymph node, occur, but within the normal vaccine initiation figures. There were also cases of COVID-19 after vaccination, but all of them fall within a period of up to two weeks after the injection, that is, before the immunity acquired was established. Neither the vaccine nor COVID-19 were associated with patient deaths (6 episodes in total). Both of them occurred in chronic disease subjects.

    During the analysis of the certification application, all such data will be checked again. In the coming weeks, a decision could be taken, but the market is betting it will be unambiguously positive. Pfizer and BioNTech shares have risen in recent sessions. Starting on Monday, the former rose by 3.74 percent in total while the later stock gained 2.34 percent. The rise comes in the midst of a report by a number of investment firms of target prices for these stocks.

    In our view, shares of both vaccine developers have now reached their equal amount. Pfizer has the potential to fall by at least 5 percent in the medium term and up to 15 percent with a likely correction in the indexes. At a drop to $40, and at a rapid breakout of this level-from $37 each, we suggest entering the company’s shares. BioNTech has a more substantial speculative overhang, with its shares being able to change by 20% even with a neutral external backdrop in the coming months.

    In Wednesday session, Pfizer stock dropped by -1.67% while that of BioNTech was down -4.14%.

  • Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) buzzing as the U.K permits vaccine use

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) buzzing as the U.K permits vaccine use

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) just revealed the Regulatory Body for Medicines & Healthcare Goods (MHRA) in the U.K.  has given temporary permission for emergency use of their mRNA (BNT162b2) vaccine against COVID-19. This constitutes the first sanction for immediate use after a Phase 3 worldwide trial of a vaccine to combat the pandemic. Pfizer and BioNTech expect more regulatory decisions across the globe in the coming days and weeks and can supply vaccine doses following possible regulatory authorizations or approvals. The U.K. delivery priority would be set according to the groups identified in the Joint Committee on Vaccination and Immunisation guidelines (JCVI).

    This year, Pfizer and BioNTech signed a partnership with the U.K. that once approved for emergency use, to provide 30 million doses of BNT162b2 mRNA-based vaccine. In early October, the deal was expanded to 40 million doses. The 40 million doses will be distributed in phases across 2020 and 2021 to ensure an equal distribution of vaccinations across geographies of contracts executed. Now that the vaccine is approved in the United Kingdom, businesses will take prompt steps to distribute the vaccine doses. It is predicted that the first doses will arrive in the U.K. With absolute distribution fulfillment expected in 2021, in the coming days.

    The firms have applied with the U.S. for Emergency Use Permission. Following rolling applications to the European Medicines Agency (EMA) and many other regulatory bodies around the world, the Food and Drug Administration (FDA) has applied the final Conditional Marketing Authorization Application (CA).

  • Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Moderna Inc (MRNA) was up 20.24%on Monday at $152.74. The biotechnology company has therefore applied for marketing authorizations for its coronavirus vaccine in the United States and Europe, which has been shown to be more than 94% successful in advanced clinical trials.

    Pfizer Inc (PFE) gained 2.90 percent to $38.31 and BioNTech SE (BNTX) added 12.96 percent to close at $124.24 on Monday. The drug manufacturing companies were able to receive regulatory approvals in the United Kingdom and the United States for their 95 percent successful vaccine candidate within a few days.

    Novavax Inc (NVAX) saw a rise of 10.99 percent to conclude the trading at $139.50. Stock of soared, while the biotechnology company again postponed the launch in the United States of a Phase III clinical trial of its Covid experimental vaccine, but cited a possible start-up in the coming weeks.

    S&P Global Inc (SPGI) was up 2.99 percent to $351.78. As expected, it announced IHS Markit’s acquisition of $44 billion in shares, the biggest merger and value acquisition since the beginning of the year. The total capitalization of IHS Markit is $37 billion.

    Airbnb is looking for a $30 billion to $33 billion valuation for its Wall Street IPO. Food distribution player, DoorDash, with its more than tripled sales in nine months and first quarterly profit, is also greedy for its IPO with a cap from $25 billion to $28 billion. Both companies are planning to join the Wall Street in mid-December.

    Netflix Inc (NFLX) slipped -0.13 percent to $490.70 in the last session. The video streaming service is expected to begin disclosing revenue of more than GBP 1 billion from British subscribers to tax authorities in the UK, according to the Guardian. The Guardian claims that Netflix’s decision could place pressure on other U.S. tech giants such as Google or Amazon, who are currently preventing such reporting by optimizing their taxation.

  • BioNTech (NASDAQ: BNTX) And Pfizer Starts Rolling Submission For COVID-19 Vaccine Candidate

    BioNTech (NASDAQ: BNTX) And Pfizer Starts Rolling Submission For COVID-19 Vaccine Candidate

    BioNTech SE (NASDAQ: BNTX) and Pfizer, Inc. (NYSE: PFE) has announced today that they have started the rolling submission to the European Medicines Agency (EMA) to get approval for the COVID-19 vaccine candidate BNT162b2. European Medicines Agency (EMA) took the decision of review after seeing the promising preliminary results from pre-clinical and early clinical studies in adults.

    The preclinical study disclosed that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2, the virus which caused the COVID-19 disease. The study proved that the combination of antibody and T cell are important tools against the novel coronavirus.

    Pfizer and BioNTech have disclosed that they are planning to work closely with the EMA’s Committee for Medicinal Products for Human Use (CHMP) to finalize the rolling review process to enable the final Marketing Authorization Application (MAA). In rolling review, CHMP has started evaluating data generated in pre-clinical trials.

    The term “rolling review” means that the regulatory authority has begun evaluating the first batch of data on the vaccine. In the rolling review of BNT162b2, the European Medicines Agency (EMA) will evaluate the real-time data which the company gathered after giving doses to patients in different trials. Instead of submitting all that data at once, it is better to start the rolling review so that the company will be able to know where its vaccine candidate stands.

    Shares of BioNTech (NASDAQ: BNTX) traded up 6.49% as it gained +5.24 at $85.94 during the trading session of Tuesday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $12.52 and a high range of $105.00. It has moved up 586.15% from its 52-weeks low and moved down -18.15% from its 52-weeks high. This company market capitalization has remained high, hitting $18.96 billion at the time of writing.

    On the other hand, Pfizer Inc. (NYSE: PFE) shares were trading down 0.20% as it lost -0.08 during at the time of writing on Tuesday. Pfizer Inc. share price went from a low point around $27.88 to briefly over $ in p40.97ast 52 weeks, though shares have since pulled back to $36.67. PFE market cap has remained high, hitting $204.16 Billion at the time of writing.

    The BNT162b2 vaccine candidate is based on the proprietary mRNA technology of BioNTech. It is supported by Pfizer’s global vaccine development and manufacturing capabilities. BioNTech aimed to develop a potential vaccine at this period of uncertainty where COVID-19 is spreading all around the world.